JP2019514393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514393A5 JP2019514393A5 JP2018557312A JP2018557312A JP2019514393A5 JP 2019514393 A5 JP2019514393 A5 JP 2019514393A5 JP 2018557312 A JP2018557312 A JP 2018557312A JP 2018557312 A JP2018557312 A JP 2018557312A JP 2019514393 A5 JP2019514393 A5 JP 2019514393A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- nucleic acid
- acid molecule
- composition
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022029582A JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331906P | 2016-05-04 | 2016-05-04 | |
| US62/331,906 | 2016-05-04 | ||
| PCT/US2017/031171 WO2017192924A1 (en) | 2016-05-04 | 2017-05-04 | Cell-based neoantigen vaccines and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029582A Division JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514393A JP2019514393A (ja) | 2019-06-06 |
| JP2019514393A5 true JP2019514393A5 (enExample) | 2020-06-11 |
| JP7033549B2 JP7033549B2 (ja) | 2022-03-10 |
Family
ID=58739362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557312A Active JP7033549B2 (ja) | 2016-05-04 | 2017-05-04 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
| JP2022029582A Pending JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029582A Pending JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11723962B2 (enExample) |
| EP (1) | EP3452082A1 (enExample) |
| JP (2) | JP7033549B2 (enExample) |
| CA (1) | CA3022267A1 (enExample) |
| WO (1) | WO2017192924A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3047313A1 (en) | 2016-12-16 | 2018-06-21 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP2020517247A (ja) | 2017-04-18 | 2020-06-18 | イエール ユニバーシティ | Ｔリンパ球ゲノム操作のためのプラットフォームおよびそのインビボハイスループットスクリーニング法 |
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| CA3081479A1 (en) * | 2017-11-06 | 2019-05-09 | Ludwig Institute For Cancer Research Ltd | Method for expansion of lymphocytes |
| WO2019094396A1 (en) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| CN111954680B (zh) * | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| WO2019147604A2 (en) * | 2018-01-23 | 2019-08-01 | Vanderbilt University | Self-antigen specific t-cells as vacines for augmenting engraftment and stability of autologous transfer |
| WO2019173441A1 (en) * | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing populations of cells and retroviral reagents for adoptive cell immunotherapy |
| CA3096708A1 (en) | 2018-04-18 | 2019-10-24 | Yale University | Compositions and methods for multiplexed tumor vaccination with endogenous gene activation |
| CA3099388A1 (en) * | 2018-04-25 | 2020-02-20 | The Methodist Hospital System | Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy |
| AU2019275070A1 (en) * | 2018-05-23 | 2021-01-14 | Gritstone Bio, Inc. | Immune checkpoint inhibitor co-expression vectors |
| US12528848B2 (en) * | 2018-05-25 | 2026-01-20 | The Wistar Institute Of Anatomy And Biology | Tumor-specific neoantigens and methods of using the same |
| WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| US20210340201A1 (en) | 2018-08-22 | 2021-11-04 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| JP7558935B2 (ja) | 2018-11-09 | 2024-10-01 | フレッド ハッチンソン キャンサー センター | メソテリンを標的とする免疫療法 |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| US20220096547A1 (en) * | 2019-01-03 | 2022-03-31 | Nanjing Legend Biotech Co., Ltd. | Modified immune cells expressing flagellin polypeptide |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| JP7711045B2 (ja) * | 2019-09-02 | 2025-07-22 | アンスティテュ・クリー | 腫瘍ネオアンチゲンペプチドを標的とする免疫療法 |
| CN110804594B (zh) * | 2019-11-21 | 2020-11-20 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞及其在用于活化cd3+免疫细胞中的应用 |
| KR102937659B1 (ko) | 2020-02-19 | 2026-03-10 | 우시 바이올로직스 아일랜드 리미티드 | 강화된 발현 시스템 및 그 사용방법 |
| CN113318225B (zh) * | 2020-02-28 | 2024-01-19 | 无锡派列博生物医药科技有限公司 | 肿瘤免疫增强剂及其制法和应用 |
| AU2021253641B2 (en) * | 2020-04-07 | 2026-08-06 | Evaxion Biotech A/S | Neoepitope immunotherapy with APC targeting unit |
| GB202006254D0 (en) * | 2020-04-28 | 2020-06-10 | Institute Of Cancer Res | Anti-cancer vaccines and related therapy |
| CN111690609B (zh) * | 2020-06-30 | 2022-04-05 | 深圳裕泰抗原科技有限公司 | 一种新生抗原免疫原性的测试方法 |
| US20230260594A1 (en) * | 2020-07-30 | 2023-08-17 | Evaxion Biotech A/S | Process for preparation of neopepitope-containing vaccine agents |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| WO2022067038A1 (en) * | 2020-09-25 | 2022-03-31 | President And Fellows Of Harvard College | Immunotherapeutic virus for the treatment of cancer |
| AR124826A1 (es) * | 2021-02-08 | 2023-05-10 | Hutchinson Fred Cancer Res | Sistema y métodos para vincular la señalización de cd40 a la unión del antígeno |
| KR20240157693A (ko) * | 2022-03-10 | 2024-11-01 | 시티 오브 호프 | 세포 면역요법을 위한 막-결합 il-12 |
| US20260191956A1 (en) * | 2022-11-28 | 2026-07-09 | The Trustees Of The University Of Pennsylvania | In vivo expansion of car t cells and delivery of car target antigen to tumors using mrna lipid nanoparticles |
| CN117338914B (zh) * | 2023-10-27 | 2024-09-06 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
| KR20260111629A (ko) * | 2023-11-06 | 2026-07-15 | 이뮤니티바이오, 인크. | 바이러스로 교육된 t 세포 |
| WO2025185599A1 (zh) * | 2024-03-04 | 2025-09-12 | 清华大学 | 编码膜型IL-12细胞因子佐剂的mRNA肿瘤疫苗及其用途 |
| CN119823283B (zh) * | 2025-01-08 | 2025-08-26 | 国科明耀(山东)医学科技有限公司 | 一种il-12-cd137嵌合蛋白、一种功能增强型工程化nk细胞、其制备及应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US20020164318A1 (en) | 1997-02-18 | 2002-11-07 | Houghton Alan N. | Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| KR101114784B1 (ko) * | 2002-11-12 | 2012-02-27 | 예일 유니버시티 | 아데노바이러스 벡터 백신 |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2005107381A2 (en) | 2004-05-07 | 2005-11-17 | Hans-Gustaf Ljunggren | Use of flagellin as an adjuvant for vaccine |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| WO2006120439A2 (en) | 2005-05-10 | 2006-11-16 | Avaris Ab | Cellular vaccine and use thereof |
| US20090324630A1 (en) | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| JP6117515B2 (ja) | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | 髄膜腫治療用医薬組成物 |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| EP3119893A1 (en) | 2014-03-17 | 2017-01-25 | Taplmmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| CA2961179A1 (en) | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| RU2716716C2 (ru) | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| WO2016069641A1 (en) | 2014-10-28 | 2016-05-06 | Thomas Jefferson University | COMPOSITIONS AND METHODS OF USING TRANSFER RNAS (tRNAs) |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| EP3355980B1 (en) | 2015-10-01 | 2025-05-14 | QXMedical, LLC | Catheter structure with improved support |
| WO2017077008A1 (en) | 2015-11-03 | 2017-05-11 | Hochschule Darmstadt | Selective hdac8 inhibitors and their uses |
-
2017
- 2017-05-04 WO PCT/US2017/031171 patent/WO2017192924A1/en not_active Ceased
- 2017-05-04 CA CA3022267A patent/CA3022267A1/en active Pending
- 2017-05-04 US US16/098,808 patent/US11723962B2/en active Active
- 2017-05-04 EP EP17724681.6A patent/EP3452082A1/en active Pending
- 2017-05-04 JP JP2018557312A patent/JP7033549B2/ja active Active
-
2022
- 2022-02-28 JP JP2022029582A patent/JP2022091750A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| US20200360431A1 (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| TWI904120B (zh) | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 | |
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| CN112203725B (zh) | Bcma嵌合抗原受体及其用途 | |
| JP6588060B2 (ja) | 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用 | |
| US20200371091A1 (en) | Bcma-targeting chimeric antigen receptor, and uses thereof | |
| JP7033549B2 (ja) | 細胞に基づくネオ抗原ワクチンおよびその使用 | |
| ES3006158T3 (en) | Methods of making chimeric antigen receptor -expressing cells | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| JP2022512968A (ja) | Ｔ細胞操作のための組成物および方法 | |
| JP2024073656A (ja) | 生体内での存続性及び治療活性及びその増殖のためのｎｋｔ細胞サブセット | |
| CN110582488A (zh) | 具有增强功效的免疫效应细胞疗法 | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| Mussafi et al. | Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer | |
| Yu et al. | CAR NK cell therapy for solid tumors: potential and challenges | |
| Pu et al. | Advances inadoptive cellular immunotherapy andtherapeutic breakthroughs inmultiple myeloma | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| CN116322717A (zh) | 否决car-t细胞 | |
| Rapoport et al. | Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies |